Skyrizi (risankizumab) – a quick pricing snapshot
| Region | Approximate cost per year | Notes |
|--------|---------------------------|-------|
| United States | $6,000–$6,500 | Most patients pay this amount before insurance. With typical Medicare Part D or private plans, the out‑of‑pocket cost can drop to a few hundred dollars, depending on coverage. |
| Canada | CAD 8,000–9,000 | The provincial drug plans negotiate a lower price, but co‑pay can still be several hundred dollars. |
| United Kingdom | £1,300–£1,500 | NHS reimbursement is negotiated; patients usually pay nothing if on the NHS. |
| Europe (generic) | €4,000–€5,500 | Prices vary by country; many have national formularies that set reimbursement levels. |
| Australia | AUD 2,600–3,200 | Part of the PBS (Pharmaceutical Benefits Scheme) after a few years of use. |
Why the price looks high
- Development costs: Skyrizi is a biologic monoclonal antibody, and the research & development phase can cost billions of dollars.
- Manufacturing: Biologics are produced in living cells, making them more expensive to scale than small‑molecule drugs.
- Insurance & rebates: The list price you see is the “MS‑Price” (Manufacturer’s Suggested Price). Insurers negotiate rebates or require prior authorization, which often reduces what you ultimately pay.
How to make it more affordable
| Strategy | How it works | Where to start |
|----------|--------------|----------------|
| Insurance coverage | Most U.S. plans cover Skyrizi, but you may need a prior authorization. | Contact your plan’s pharmacy benefits manager or call the Skyrizi help line. |
| Manufacturer assistance | Skyrizi’s manufacturer (Amgen) offers a Patient Assistance Program (PAP) for those who qualify. | Visit Amgen’s Skyrizi PAP portal or call their helpline. |
| Generic alternatives | Once a biosimilar (e.g., Koplik or Sakairi) receives FDA approval, prices may drop. | Ask your dermatologist if a biosimilar is available and covered. |
| Specialty pharmacy programs | These pharmacies sometimes negotiate lower co‑pays for high‑cost biologics. | Your dermatologist’s office can connect you with a specialty pharmacy. |
| Clinical trials | Some patients are eligible for trials that provide Skyrizi at no cost. | Talk to your provider about ongoing studies. |
Quick FAQ
- Do I have to pay the full $6,000 in the U.S.?
No. Most insurance plans will cover a large portion; the out‑of‑pocket cost can be as low as a few hundred dollars, depending on your plan’s formulary and step‑therapy requirements.
- How do I find out if my plan covers Skyrizi?
Check your plan’s formulary online or call the member services line. The dermatologist’s office can also submit a prior authorization on your behalf.
- Can I get a lower price if I pay cash?
Some pharmacies offer a discount for cash, but it’s often only a 5–10% reduction. Manufacturer PAPs usually provide a better deal.
- What happens if my insurance denies coverage?
Ask your provider to appeal the decision. Often the denial is due to a step‑therapy requirement that can be satisfied with another biologic or oral medication before moving to Skyrizi.
---
Bottom line: Skyrizi’s list price is around $6,000–$6,500 per year in the U.S., but most patients pay far less thanks to insurance, manufacturer programs, and potential biosimilars. If cost is a concern, talk to your dermatologist or pharmacist about these options—they can often help you find a plan or assistance program that fits your budget.